Added to YB: 2026-09-08
Pitch date: 2026-09-05
PMVP [neutral]
PMV Pharmaceuticals, Inc.
Author Info
I research and share thesis-driven ideas on potential healthcare multibaggers. Sign up for the newsletter.
Company Info
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
Market Cap
$97.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.23
P/E
-0.91
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
This Week in Healthcare - Issue #1 - PMV Pharmaceuticals, Inc.
PMVP (update): PMV reported a 46% overall response rate in 76 platinum-resistant and refractory ovarian cancer patients, with a 10.0-month median response duration and mostly Grade 1-2 treatment-related adverse events. FDA feedback supports an accelerated-approval NDA submission for rezatapopt in TP53 Y220C-mutant platinum-resistant and refractory ovarian cancer, targeted for Q1 2027. Primary analysis data from all Phase 2 cohorts is planned for a Q4 2026 medical conference. PMV also priced an oversubscribed offering with approximately $50.8M in gross proceeds before costs.
Read full article (1 min)